恩必普软胶囊治疗短暂性脑缺血发作患者的疗效及对相关因子的影响

doi:10.3969/j.issn.1671-7171.2023.09.029

摘要
图/表
参考文献(13)
相关文章 (15)

全文: PDF (1149 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨恩必普软胶囊治疗短暂性脑缺血发作(TIA)患者的疗效及对相关因子的影响。【方法】110例TIA患者随机分为观察组和对照组,每组55例。在给予常规治疗的基础上,观察组患者口服恩必普软胶囊治疗,对照组口服拜阿司匹林肠溶片治疗,两组均连续治疗14 d。比较两组临床疗效及治疗前后炎症因子[血清超敏C反应蛋白(hs-CPR)、同型半胱氨酸(Hcy)、白介素-6(IL-6)、基质金属蛋白酶-9(MMP-9)]、血液流变学指标[全血黏度低切(LS)、全血黏度高切(HS)、血浆黏度(PV)]、凝血功能指标[纤维蛋白原(FIB)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)]、神经功能指标[神经功能因子S-100B蛋白(S-100B)、神经元特异性烯醇化酶(NSE)]水平的变化。【结果】观察组总有效率为92.73%(51/55),显著高于对照组的78.18%(43/55),且差异有统计学意义(P<0.05)。两组治疗前各项指标比较,差异均无统计学意义(P>0.05);两组治疗后Hcy、hs-CRP、IL-6、MMP-9较治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05);两组治疗后LS、HS、PV较治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05);两组治疗后FIB较治疗前显著降低,PT、APTT显著升高(P<0.05),且观察组治疗后FIB显著低于对照组,PT、APTT显著高于对照组(P<0.05);两组治疗后S-100B、NSE较治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05)。【结论】恩必普软胶囊治疗TIA疗效显著,可有效抑制炎症反应,对患者的血液流变学、凝血功能及神经功能有明显改善。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄亮
	贾军
	屈兴汉

关键词 ：脑缺血发作,短暂性/药物疗法, 软胶囊, 治疗结果

Abstract：【Objective】To explore the therapeutic effect of Enbipu capsules on transient ischemic attack (TIA) patients and its impact on related factors.【Methods】A total of 110 TIA patients were randomly divided into two groups,with 55 cases in each group. All patients received conventional treatment for TIA. The observation group was orally administered Enbipu capsules,while the control group was given enteric-coated aspirin tablets. Both groups were treated continuously for 14 days. The clinical efficacy,changes in inflammatory factors [serum hypersensitive C-reactive protein (hs-CRP),homocysteine (Hcy),interleukin-6 (IL-6),and matrix metalloproteinase-9 (MMP-9)],hemorheology indicators [whole blood viscosity at low shear rate (LS),whole blood viscosity at high shear rate (HS),and plasma viscosity (PV)],coagulation function indicators [fibrinogen (FIB),prothrombin time (PT),activated partial thromboplastin time (APTT)],and neurological function indicators [neurofunctional factor S-100B protein (S-100B) and neuron-specific enolase (NSE)] were compared between the two groups.【Results】The overall effective rate in the observation group was 92.73% (51/55),which was significantly higher than the 78.18% (43/55) in the control group with statistically significant difference (P<0.05). There were no significant differences of all indicators in both groups before treatment (P>0.05). Post-treatment levels of Hcy,hs-CRP,IL-6,and MMP-9 in both groups were significantly reduced compared to pre-treatment (P<0.05). And the post-treatment levels of Hcy,hs-CRP,IL-6,and MMP-9 in the observation group were significantly lower than those in the control group after treatment(P<0.05). Compared to before treatment,levels of LS,HS,and PV decreased significantly after treatment in both groups (P<0.05),while LS,HS and PV levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment,FIB in both groups decreased significantly,while PT and APTT increased significantly (P<0.05); And FIB in the observation group after treatment was significantly lower than that in the control group after treatment,while both PT and APTT of the observation group after treatment were higher than those of the control group after treatment (P<0.05). S-100B and NSE levels after treatment in both groups decreased significantly if compared to pre-treatment (P<0.05); And levels of S-100B and NSE in the observation group were much lower than those in the control group (P<0.05).【Conclusion】Enbipu capsules have a significant therapeutic effect on TIA,which can effectively suppress inflammatory responses and significantly improve patients' hemorheology,coagulation function,and neurological function.

Key words： Ischemic Attack,Transient/DT Soft Capsule Treatment Outcome

收稿日期: 2022-08-03

中图分类号:

R743.31

通讯作者: *E-mail:qxhdyx000000.@163.com

引用本文:

黄亮, 贾军, 屈兴汉. 恩必普软胶囊治疗短暂性脑缺血发作患者的疗效及对相关因子的影响[J]. 医学临床研究, 2023, 40(9): 1385-1388.
HUANG Liang, JIA Jun, QU Xinghan. Therapeutic Effect of Enbipu Capsules on Transient Ischemic Attack Patients and its Impact on Related Factors. JOURNAL OF CLINICAL RESEARCH, 2023, 40(9): 1385-1388.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.09.029 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I9/1385

[1] DALLI L L,KIM J,CADILHAC D A,et al. Greater adherence to secondary prevention medications improves survival after stroke or transient ischemic attack: a linked registry study[J].Stroke,2021,15(4):314-319.
[2] LINDENHOLZ A,KOLK A,SCHAAF I,et al. Intracranial atherosclerosis assessed with 7-T MRI: evaluation of patients with ischemic stroke or transient ischemic attack[J].Radiology,2020,295(1):190-193.
[3] 刘潺. 血栓弹力图与常规凝血四项指标评价急性脑卒中抗血小板药物治疗后患者凝血功能的变化及其相关性[J].医学临床研究,2020,37(6):915-917.
[4] LI Z X,XIONG Y,GU H Q,et al. P2Y12 inhibitors plus aspirin versus aspirin alone in patients with minor stroke or high-risk transient ischemic attack[J].Stroke,2021,52(7):2250-2257.
[5] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J].中华神经科杂志,2015,48(4):258-273.
[6] 常春红,王光胜,杨同慧,等. 氯吡格雷应用于短暂性脑缺血发作治疗中的价值及对IL-6、MMP-9的影响[J].检验医学与临床,2018,15(1):124-127.
[7] WEI M,XUE X,PAN Y,et al. Relationship between thrombomodulin gene polymorphism and susceptibility to venous thromboembolism: A protocol for systematic review and meta-analysis[J].Medicine,2021,100(4):31-36.
[8] 薛有平,雷毅,刘峰,等. 短暂性脑缺血发作患者的血清生化指标的相关性研究[J].中华老年心脑血管病杂志,2018,20(3):275-277.
[9] 吴从印,陈娟,冯光球,等. 老年缺血性脑血管病患者血管内皮细胞功能指标与沉默信息调节因子1的相关性分析[J].中国医药,2019(4):549-552.
[10] 王春,谢静,骆嵩,等. 基质金属蛋白酶-9与短暂性脑缺血发作预后相关性分析[J].临床和实验医学杂志,2021,20(22):2382-2386.
[11] 杨光,程越朋,孙鑫. 银杏内酯联合丁苯酞对急性脑梗死患者神经功能缺损及炎症介质的影响[J].心脑血管病防治,2019,19(4):363-365.
[12] 李宏建. 替格瑞洛联合阿司匹林或单用阿司匹林治疗急性缺血性卒中或短暂性脑缺血发作[J].国际脑血管病杂志,2020,28(11):862-863.
[13] 郭强,张恒,翟洁敏,等. 丁苯酞软胶囊与拜阿司匹林肠溶片治疗短暂性脑缺血发作效果比较[J].解放军医药杂志,2020,32(4):68-71.